Rapid deterioration in quality of life during interleukin-2- and α-interferon-based home therapy of renal cell carcinoma is associated with a good outcome

British Journal of Cancer

Volumn 89, Issue 1, 2003, Pages 50-54

  Atzpodien, J ^a,b,c,d   Kuchler Th ^d   Wandert, T ^b   Reitz, M ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Europaisches Institut fur Tumor Immunologie und Pravention   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

Author keywords

Alpha interferon; Interleukin 2; Quality of life; Renal cell carcinoma

Indexed keywords

ALPHA2A INTERFERON; CAPECITABINE; FLUOROURACIL; INTERLEUKIN 2; ISOTRETINOIN;

AGED; ANOREXIA; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; COGNITION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DYSPNEA; EMOTION; FATIGUE; FEMALE; HEALTH STATUS; HOME CARE; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MALE; NAUSEA; OUTPATIENT CARE; PAIN; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SLEEP DISORDER; SOCIAL ASPECT; TREATMENT OUTCOME; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; HEALTH STATUS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; INTERLEUKIN-2; ISOTRETINOIN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OUTPATIENTS; PROGNOSIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0042345060     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600996     Document Type: Article

References (14)

1. Aaronson NK, Bullinger M, Ahmedzai S (1988) A modular approach to quality-of-life assessment in cancer clinical trials. Recent Results Cancer Res 111: 231-249
2. Aaronson NK, Ahmedzai S, Bergmann B, Bullinger M (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376
3. Atzpodien J, Korfer A, Franks CR, Knuver-Hopf J, Lopez-Hanninen E, Fischer M, Mohr H, Dallmann I, Hadam M (1990) Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 335: 1509-1512
4. Atzpodien J, Lopez HE, Kirchner H, Bodenstein H, Pfreundschuh M, Rebmann U, Metzner B, Illiger HJ, Jakse G, Niesel T (1995) Multi-institutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13: 497-501
5. Biermann CW, Küchler Th (1999) Lebensqualität in der urologischen Onkologie. Urologe A 38: 189-200
6. Doyle C, Crump M, Pintilie M, Oza AM (2001) Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and cost in woman receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19(5): 1266-1274
7. Elson PJ, Witte RS, Trump DL (1988) Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48: 7310
8. Fayers P, Aaronson B, Bjordal K, Carran D, Groenvold M On behalf of the EORTC Study Group (2000) EORTC QLQ C30 Scoring Manual. Brussels, Belgium: European Organization for Research and Treatment of Cancer, 3rd edition
9. Geels P, Eisenhauer E, Bezjak A, Zee B, Day A (2000) Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18(12): 2395-2405
10. Heinzer H, Mir TS, Huland E, Huland H (1999) Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J Clin Oncol 17(11): 3612-3620
11. Joffe JK, Patel PM, Banks RE, Selby PJ (1996) Cytokines in combination with chemotherapy for advanced renal carcinoma - the importance of patient selection. Cancer Biother Radiopharm 11(5): 309-313
12. Kornblith A, Herndon II E, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Elloton J, Larson RA, Scriffer CA, Holland JC (2002) Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a cancer and leukemia group B study. J Clin Oncol 20(10): 2442-2452
13. Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health related quality of life scores. J Clin Oncol 16: 139-144
14. Sleijfer DT, Janssen RA, Buter J, de Vries EG, Willemse PH, Mulder NH (1992) Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 10: 1119-1123